1	Full title:
2	Pulmonary haemorrhage as a frequent cause of death among patients with
3	severe complicated Leptospirosis in Southern Sri Lanka
4	Short title:
5	Pulmonary haemorrhage and severe Leptospirosis
6	
7	¹ Fonseka CL, ¹ Dahanayake NJ, ² Mihiran DJD, ² Mithunika AWK, ² Nawanjana HLL,
8	² Wickramasuriya HS, ⁴ Wijayaratne WMDGB, ⁴ Sanjaya K, ¹ Bodinayake CK.
9	
10	¹ Department of Internal Medicine, Faculty of Medicine, University of Ruhuna, Galle
11	² Faculty of Medicine, University of Ruhuna, Galle
12	³ Department of Microbiology, Faculty of Medicine, University of Ruhuna, Galle
13	⁴ Department of Limnology and Water Technology, Faculty of Fisheries and Marine Sciences &
14	Technology, University of Ruhuna
15	Corresponding author: <u>fonseka.lakmal@gmail.com</u>
16	
17	Abstract

Background: Leptospirosis is a tropical disease associated with life threatening complications. 18 19 Identifying clinical and investigation-based parameters that predict mortality and morbidity is vital to provide optimal supportive care. Methods: We conducted a prospective observational study in 20 21 an endemic setting, in the southern Sri Lanka. Consecutive patients having complicated leptospirosis were recruited over 18 months. Clinical, investigational and treatment data were 22 23 collected and the predictors of mortality were analysed. Results: Out of 88 patients having 24 complicated leptospirosis, 89% were male. Mean age was 47yrs (+16.0). Among the total, 94.3% had acute kidney injury, 38.6% had pulmonary haemorrhages, 12.5% had fulminant hepatic 25

failure, 60.2% had hemodynamic instability and 33% had myocarditis. An acute significant 26 27 reduction of haemoglobin (Hb) was observed in 79.4% of patients with pulmonary haemorrhage. 28 The mean Hb reduction of patients with pulmonary haemorrhage was 3.1g/dl. The presence of pulmonary haemorrhage (PH) and hemodynamic instability within first 48 hours of admission 29 significantly predicted mortality(p<0.05) in severe Leptospirosis. Additionally, within first 48 30 hours of admission, elevated SGOT, presence of atrial fibrillation, presence of significant 31 32 haemoglobin reduction, higher number of inotropes used, prolonged shock, invasive ventilation and admission to ICU significantly predicted morality. Out of organ complications in the first week 33 of illness, pulmonary haemorrhage and fulminant hepatic failure (FHF) combination had 34 significant adjusted odds of mortality (OR=6.5 and 4.8, p<0.05). Six patients with severe 35 respiratory failure due to PH underwent ECMO and four survived. The overall mortality in 36 37 complicated leptospirosis was 17%. In PH and FHF, the mortality rate was higher reaching 35.4% and 54.5%, respectively. Conclusions: Within first 48 hours of admission, organ complications 38 39 such as pulmonary haemorrhage and haemodynamic instability and other parameters such as atrial 40 fibrillation, acute haemoglobin reduction, elevated SGOT level could be used as early parameters 41 predictive of mortality in severe Leptospirosis. PH and FHF within the first week of admission in leptospirosis are associated with high morbidity and mortality requiring prolonged ICU care and 42 43 hospitalisation. Above parameters could be used as parameters indicating severity for triaging and 44 intensifying treatment. Using ECMO is a plausible treatment option in patients with severe 45 pulmonary haemorrhage.

Keywords: Leptospirosis, Pulmonary Haemorrhage, Lung haemorrhage, alveolar haemorrhage
 Fulminant Hepatic Failure, Extracorporeal Membrane Oxygenation, Predictors of mortality

48 Author summary

Leptospirosis is a tropical infectious disease predominantly affecting the lower socioeconomic groups in Sri Lanka. It is associated with significant morbidity and mortality, especially in an endemic setting. Hence, it is vital to identify clinical and biochemical parameters that can predict mortality for triaging and for escalation of care. We observed that pulmonary haemorrhage, myocarditis, hemodynamic instability and hepatic dysfunction are frequent complications of leptospirosis in southern Sri Lanka. Additionally, we identified that mortality was associated with the presence of two major complications of leptospirosis: pulmonary haemorrhage and

haemodynamic instability. Therefore, early detection of these two complications along with other 56 57 parameters that predict mortality such as elevated SGOT levels on admission, acute haemoglobin 58 reduction, atrial fibrillation, prolonged shock and need for invasive ventilation would assist to recognise critically ill patients. Within the first week of admission, PH and development of FHF 59 predicted mortality. One-third our population had acute kidney injury in isolation and they had 60 lesser mortality. Other organ complications were almost always detected in combination and were 61 62 associated with a higher mortality. Pulmonary haemorrhage was detected in one-third of patients and the majority warranted intensive care. Other than usual treatment modalities, ECMO 63 (Extracorporeal Membrane Oxygenation) was used in six patients with critical respiratory failure 64 due to pulmonary haemorrhage, where four survived. Out of the total group of complicated 65 leptospirosis, in excess of one-third required intensive care treatment and 17% succumbed. 66 Additionally, we mapped the leptospirosis prevalence rate in Galle district, and observed that 67 severe cases are detected in specific localities. These features are helpful in early detection of 68 severe disease and proactive management for those who are having predictors of mortality. 69

70

71 Introduction

Leptospirosis has emerged as a major health threat in tropical and even in sub-tropical settings, estimated to infect more than a million people with approximately 60,000 deaths annually[1]. Natural disasters and extreme weather events including floods are now recognized to precipitate leptospirosis related epidemics [2] and its emergence in tropical settings is observed even in Sri Lanka[3]. Severe leptospirosis is characterized by dysfunction of multiple organs including the liver, kidneys, lungs, and brain. The combination of jaundice and renal failure was commonly known as Weil's disease[4].

The major burden attributed to leptospirosis is due to its severe life-threatening manifestations such as acute renal failure, myocarditis, pulmonary haemorrhage and liver involvement. Out of the life-threatening manifestations, pulmonary haemorrhage (PH) is recognized as the most fatal. This life-threatening complication was observed to be prevalent in several leptospirosis endemic countries such as Nicaragua, El Salvador, Sri Lanka and Greece [5-8]. The case fatality for pulmonary haemorrhage syndrome was reported to be more than 50% [9], but in an endemic setting

it could be as high as 100%[10-12]. A recent review noted 1.4-45.4% of lung involvement among
hospitalized patients in Sri Lanka[13], and a recent study done in southern Sri Lanka mentioned
an incidence just above 60%[14].

88 Different studies have mentioned parameters or manifestations that can be associated with 89 mortality from Leptospirosis. Few studies have mentioned that altered mental status, oliguria, and 90 respiratory insufficiency, hypotension, arrythmias were independently associated with death[15-91 17]. Out of organ related complications, acute kidney injury (AKI) is found to be the most common 92 manifestation with a median series mortality around 10%[18]. Myocarditis was found in 7-15% 93 of confirmed cases in Sri Lanka[19, 20]. Hepatic involvement is common and can commonly 94 present as slight disturbances in serum liver function tests. However, fulminant hepatic failure is 95 occasionally reported as a recognised complication in a few instances of severe leptospirosis[21]. 96 It was evident that frequency of the complication could vary depending on the infecting serovar 97 and geographic location.

In severe cases of pulmonary haemorrhage, some preferred using advanced therapeutic modalities such as plasmapheresis and ECMO. Although these techniques were previously reserved for developed countries, currently there are attempts to use these in developing countries where leptospirosis is endemic[22]. Currently, there is a paucity of knowledge on usage of ECMO in patients with pulmonary haemorrhage in an endemic tropical setting, only reported several case reports[22].

In our study, we describe morbidity, mortality and their predictors in a potentially severe group of leptospirosis who had organ complications, excluding relatively benign mild cases of leptospirosis without significant organ involvement. Additionally, we describe details from a large prospective case series of critically ill patients with pulmonary involvement who required ECMO.

108 Methods

109 Study sample

A prospective observational study was conducted at the Teaching Hospital Karapitiya (THK), Galle, the largest tertiary care centre in southern Sri Lanka, for 18 months, from March 2017 to September 2018. THK is the main referral center for complicated leptospirosis and for ECMO, due to its geographic location surrounding paddy farming communities. All consenting

consecutive patients meeting the criteria for complicated leptospirosis (with at least single organ 114 115 involvement) as defined below were recruited from all medical units, emergency care unit and 116 intensive care units(ICU) of THK. The criteria included patients with documented fever or a history of fever within 7 days of admission with or without myalgia with one or more of the 117 following: evidence of acute renal insufficiency without prerenal etiology: creatinine >1.5 mg/dL 118 (130µmol/L) and /or urine output less than 500mL/24h with active urinary sediments (at least two 119 120 of WBC, RBC and albumin on dipstick or >5 RBC/WBC per HPF), evidence of respiratory failure: Respiratory rate >28 cycles per min, evidence of hypoxia requiring oxygen, or requiring non-121 122 invasive or mechanical ventilation, evidence of spontaneous hemorrhage, pulmonary hemorrhage on chest radiograph or hemoptysis, conjunctival hemorrhage, epistaxis, hematuria, hematemesis, 123 hematochezia or melena, unexplained vaginal bleeding, or petechiae), evidence of cardiac 124 arrythmias or ECG changes suggestive of myocarditis or new echocardiographic abnormalities 125 suggestive of myocarditis, evidence of hepatic dysfunction - Clinical jaundice or elevated bilirubin 126 127 (total bilirubin >2mg/dL or 51.3µmol/L) or laboratory evidence of hepatitis (transaminases elevated above 2 times the upper limit of normal). Patients whose age less than 12 years, patients 128 129 who are unable or unwilling to give consent for participation, leukopenia within 48 hours prior or after hospital admission, positive rapid test, virology or serology for Dengue or infections other 130 131 than leptospirosis, evidence of focal bacterial infection as an aetiology of fever (i.e., urinary tract infection/ pyelonephritis, cellulitis, sinusitis, lobar pneumonia), evidence of end organ failure 132 133 (renal, cardiac, respiratory) due to other etiologies unrelated to the current illness were excluded from the study. 134

135 **Definitions of complications**

Oliguric renal failure was defined as urine output <0.5 ml/kg/hr and non-oliguric renal failure when urine output >0.5 mL/kg/hr. Pulmonary haemorrhage (PH) was defined from the presence of hypoxia (SpO2 <92%, paO2 < 80 mmHg/10.7 kPa) / requirement of oxygen by non-invasive or invasive methods with the presence of bilateral diffused alveolar shadows and/or drop in haemoglobin. Acute liver failure or fulminant hepatic failure was defined as the presence of PT/INR >1.5 and/or presence of hepatic encephalopathy. Cardiac involvement was defined by the presence of elevated troponin levels, changes in electrocardiogram or presence of arrythmias or

echocardiographic changes. Significant acute haemoglobin reduction due to bleeding was defined as $\geq 2g/dl$ reduction of haemoglobin within 48 hours.

145 **Data collection**

146 Clinical and epidemiological data were collected prospectively, using an interviewer administered questionnaire by a trained research assistant by conducting direct interviews of patients, and from 147 148 hospital records after obtaining written informed consent from study participants. Laboratory and 149 clinical parameters on first 48 hours of admission were used to analyse predictors of mortality. 150 When the patient was in critical condition, the consent was obtained from the next-of-kin. The patients were visited every other day by the investigators to record clinical data and laboratory 151 152 data. Follow-up was done by a brief assessment at the hospital performed one month after 153 discharge from the hospital or by a telephone conversation.

154 Laboratory conformation

Laboratory confirmation was based on the WHO LERG report, by symptoms consistent with
 leptospirosis and a single Microscopic Agglutination Test (MAT) titre ≥1:400 and/or by detection
 of *Leptospira* DNA by PCR and/or by the presence of IgM antibodies [23]. Leptospirosis PCR and
 MAT (15 pathogenic serovar panel) was performed at Medical Research Institute, Colombo, Sri

159 Lanka.

160 Spatial distribution of leptospirosis occurrence

GPS location of location of probable exposure to leptospirosis or home was recorded during the study. The spatial distribution of the patients was overlaid with the local Divisional secretariat (DS) division map of the all districts and the prevalence of leptospirosis cases per hundred thousand people in each DS division was illustrated using ArcGIS 10.3.

165 Statistical testing

All data were analyzed with SPSS version 26.0. Results were expressed by mean ± standard deviation (SD) or percentages. Comparison between the two groups was performed using Pearson's Chi-square test and Student's T test. Mann–Whitney test was used for parameters with a non-normal distribution. A logistic regression model was used for quantitative variables for binary outcome of mortality. Unadjusted odds ratios (OR) and 95% confidence intervals (CI) were

171 calculated. A multivariate logistic regression (stepwise forward and backward analysis) was 172 performed to analyze the possible risk factors associated with mortality. Significance level was set 173 at 5 % (p value ≤ 0.05).

174 **Results**

One hundred and twenty-two patients with complicated leptospirosis were recruited to the study. 175 Eighty-eight were eligible and the diagnosis was confirmed by PCR and/or MAT testing. Among 176 them, mean age was 47(+ 16.0) years, and 89% were male. Almost all patients had fever (97.7%) 177 on presentation, and myalgia (81.8%), arthralgia (78.4%), vomiting (46.6%) and headache (62.5%) 178 179 were other common symptoms. Eighty-three percent had a history showing exposure to 180 leptospirosis. Thirty-two (36.4%) patients had received ICU care. Among them, the mean duration of hospitalization was 8.07(SD±5.9) days and the mean duration of ICU care was 6.73(SD±4.9) 181 182 days. The case fatality rate of the study sample was 17% with 15 deaths, including one patient who 183 succumbed on admission to the hospital.

184 Complications associated with Leptospirosis (Table 1)

185 Acute kidney injury

Among the study group, acute kidney injury was the most common complication. Out of 88 patients, 83(94.3%) developed AKI. Among the group who had AKI, 73.9% had oliguric renal failure and 15.9% had non-oliguric renal failure. Out of the total, 30.7% (n=27) had only AKI.

189 Pulmonary Haemorrhage

Pulmonary haemorrhage (PH) was detected in 34(38.6%) patients. All of them had significant hypoxia and bilateral diffuse alveolar opacities. Out of them, 26.1% had cough and shortness of breath. Seven (8%) complained of haemoptysis on admission to the hospital. Twenty-four (70.6%) had bilateral diffused involvement in the chest radiograph and the rest (29.4%) had patchy bilateral alveolar shadows. Among patient who developed PH, all required supplementary oxygen, 15 (44.1%) were on non-invasive ventilation, 29 (79.4%) required intubation and ventilation.

196 Hemodynamic instability

- 197 Fifty-three (60.2%) had hemodynamic instability (hypotension with blood pressure $\leq 90/60$) and
- 198 47 (53.4%) patients required usage of at least one inotrope during the course of treatment. Out of
- them, in 57.4%, 25.5%, 17% patients required one, two, three or more types of inotropes,
- 200 respectively, to gain hemodynamic stability.

201 Cardiac manifestations

Out of total, 33.0% (29/88) had at least a single indicator of cardiac involvement. Elevated Troponin, abnormal ECG or an abnormality in echocardiography was detected in 18.2%, 14.8%, 11.4%, respectively. Eleven participants (12.5%) had atrial fibrillation during the illness. One had ST elevation myocardial infarction detected on admission.

206 Hepatic dysfunction

Out of total, 43 (48.9%) patients had hepatic dysfunction evidenced by deranged transaminases, ALP, total bilirubin and/or PT/INR. Thirty (34.1%) had elevated ALT and/or AST and 8 had elevated alkaline phosphate levels at the first 48 hours of the admission. Deranged PT/INR was observed at a later stage of the illness. Eleven (12.5%) patients had evidence of fulminant hepatic failure late (after 48 hours of the illness) during the course of illness. All of these individuals who fulfilled the definition of acute hepatic failure had prolonged hypotension and were supported on multiple inotropes.

214 Haematological parameters – acute haemoglobin reduction and platelet count

A significant reduction in haemoglobin (Hb) of >2g/dl within 48 hours was observed in 27 out of 215 34 (79.4%) having PH with a mean maximum Hb reduction of 3.1g/dl (+1.2, range = 1.3-5.9g/dl) 216 over 48 hours. Median day of detection of a significant haemoglobin drop was on day 5 after onset 217 218 of fever (O1=4, O3=6 days). In the non-pulmonary haemorrhage group, a minority (16.7%) had 219 significant haemoglobin reduction. The mean significant haemoglobin reduction in this group was 1.15g/dl (+1.09, range= 0-4.5). Median day of detection of a significant haemoglobin drop in the 220 non-PH group was on day 6 after onset of fever (Q1=4.75, Q3=8.75 days). The maximum mean 221 haemoglobin reduction was significantly higher in the PH group than non-PH group (p=<0.001). 222 223 Furthermore, significant hemoglobin reduction in non-PH group has occurred later than the PH 224 group (p=0.046).

- Among the whole group, 44 (50.0%) and 70 (79.5%) had platelet counts less than 50,000 cm³ and
- less than 100,000 cm³, respectively.

227 Table 1: Frequency of complications in severe leptospirosis among the study group

	Number	%
	(n=88)	
Demographic details		
Age, yrs	47(±16.0)	
Male	78	88.6
Symptoms		
Fever on presentation	86	97.7%
Myalgia	72	81.8%
Arthralgia	69	78.4%
Headache	55	62.5%
Vomiting	41	46.6%
Fatigue	31	35.2%
Calf pain	35	39.8%
Cough	23	26.1%
Hemoptysis	7	8.0%
Shortness of breath	23	26.1%
Abdominal pain	21	23.9%
Yellowing discolouration of eyes	20	22.7%
Diarrhea	27	30.7%

Reduced urine output	39	44.3%
Leptospirosis exposure in history	73	83%
Disease related complications		
Acute kidney injury	83	94.3%
Oliguric	65	73.9%
Non-oliguric	14	15.9%
Pulmonary haemorrhage	34	37.4%
Myocarditis	29	33.0%
Atrial fibrillation	11	12.5%
Hepatic dysfunction	43	48.9%
Fulminant hepatic failure	11	12.5%
Haemodynamic instability	53	60.2%
Intensive care unit admission	32	36.4%
Overall mortality	15	17%

228

229 Association of the number of major complications with mortality in severe Leptospirosis

Then, we analysed the association of major complications in patients with severe Leptospirosis within the first week after admission. Acute kidney injury, myocarditis, pulmonary hemorrhage, hepatic dysfunction and hemodynamic instability were considered as major complications.

Table 2 reveals the association of major complications among confirmed leptospirosis patients. Twenty-nine (33.0%) patients had at least one complication associated with leptospirosis. Out of them, nearly all (27 patients, 93.1%) had isolated acute kidney injury, one had isolated pulmonary haemorrhages and another had isolated hemodynamic instability mimicking septic shock. In the group of patients who had only two major complications, majority (n=13, 68.4%) had acute kidney

- 238 injury with hemodynamic instability. Increasing number of complications significantly increased
- the admission to ICU, duration of hospital stays and mortality (p=<0.05).

240 Table 2: Morbidity and Mortality in patients having major complications of severe

241 Leptospirosis

Number of	1 (n=29)	2 (n=19)	3 (n=20)	4 (n=17)	5 (n=3)	p-value		
Complications								
Complications								
1								
AKI	27	17 (89.5%)	19	17 (100%)	3 (100%)	0.711		
	(93.1%)		(95.0%)					
Pulmonary	1 (3.4%)	1 (5.3%)	13	16	3 (100%)	<0.01**		
Haemorrhage			(65.0%)	(94.1%)				
Myocarditis	0	4 (21.1%)	10	12	3 (100%)	<0.01**		
			(50.0%)	(70.6%)				
Fulminant	0	1 (5.3%)	0	7 (41.2%)	3 (100%)	<0.01**		
Hepatic Failure								
Hemodynamic	1 (3.4%)	15 (78.9%)	18	16	3 (100%)	<0.01**		
instability			(90.0%)	(94.1%)				
Morbidity & Mortality								
	1 (2 40/)	0 (10 50/)	10	14	2 (1000/)	-0.01**		
Admission to ICU	1 (3.4%)	2 (10.5%)	12	14	3 (100%)	<0.01**		
			(60.0%)	(82.4%)				
Duration of ICU	2	6.5 (<u>+</u> 2.1)	6.1 (<u>+</u> 4.4)	8 (<u>+</u> 6.1)	5.3	0.7		
care (Days)					(±3.2)			
Duration of	5.5 (<u>+</u> 1.8)	7.7 (<u>+</u> 4.1)	8.6 (<u>+</u> 4.9)	13.2	6.7	<0.01**		
hospital stay				(±9.6)	(±2.9)			
Mortality	1(3.4%)	1 (5.3%)	4 (20.0%)	6 (35.3%)	3 (100%)	<0.01**		

242

243 Early predictors of mortality in patients with severe Leptospirosis

Clinical and biochemical parameters within first 48 hours of admission were considered for 244 245 analysis. Symptoms present on admission were not predictive of mortality, which included symptoms such as haemoptysis, shortness of breath, abdominal pain etc. However, the presence 246 247 of atrial fibrillation, presence of a significant acute haemoglobin reduction, increase number of 248 inotropes used, prolonged shock, intubation and ventilation, and admission to ICU significantly 249 predicated morality in the severe leptospirosis group. Although, platelet, white cell count, serum bilirubin during admission were not predictive of mortality, high SGOT level on admission (but 250 251 not SGPT) level significantly predicted mortality (Table 3).

252 Association of organ involvement with mortality in severe Leptospirosis

We analysed whether these five major complications were predictive of mortality in patients with severe Leptospirosis (Table 3). Due to the long hospital stay in certain individuals the complications within the first week of stay in hospital was considered for this analysis. The presence of pulmonary haemorrhage (PH), fulminant hepatic failure (FHF) and hemodynamic instability significantly predicts mortality(p=<0.05). Additional analysis with stepwise logistic regression showed that, out of the five complications, PH and FHF combination were most predictive of mortality.

Table 3: Clinical indices and Major organ complications predictive of mortality in patients

261 with severe leptospirosis. (Logistic regression analysis of predictors of mortality)

	Unadjusted Odds ratio	p Value	Adjusted Odds	p Value
			ratio	
Clinical Indices				
Presence of high SGOT	5.3 (CI=1.6-17.1)	0.006*		
Atrial fibrillation	4.7 (CI=1.21-17.8)	0.22		
Presence of a significant	5.3 (CI=1.5-18.9)	0.009*		
reduction of Hb (>2g/dl				
over 48 hours)				

Number of inotropes used	10.7 (CI=2.5-45.4)	0.001*					
in shock							
Longer duration of shock /	2.5 (CI=1.07-5.9)	0.034*					
inotrope requirement							
Intubation and ventilation	18.5 (3.8-89.5)	<0.001**					
Admission to ICU	10.6 (CI=2.7-41.5)	0.001*					
Type of major organ complication							
Pulmonary Hemorrhage	9.3 (CI=2.4-36.1)	<0.001**	6.5 (CI=1.6-27.0)	0.01*			
Pulmonary Hemorrhage Fulminant Hepatic Failure	9.3 (CI=2.4-36.1) 9.1 (CI=2.3-35.9)	<0.001** 0.002*	6.5 (CI=1.6-27.0) 4.8 (CI=1.1-21.0)	0.01*			
Pulmonary Hemorrhage Fulminant Hepatic Failure Hemodynamic instability	9.3 (CI=2.4-36.1) 9.1 (CI=2.3-35.9) 12.2 (CI=1.5-97.7)	<0.001** 0.002* 0.018*	6.5 (CI=1.6-27.0) 4.8 (CI=1.1-21.0)	0.01*			
Pulmonary Hemorrhage Fulminant Hepatic Failure Hemodynamic instability Myocarditis	9.3 (CI=2.4-36.1) 9.1 (CI=2.3-35.9) 12.2 (CI=1.5-97.7)	<0.001** 0.002* 0.018* 0.07	6.5 (CI=1.6-27.0) 4.8 (CI=1.1-21.0) -	0.01*			

262

263 Comparison of mortality and morbidity in patients having Pulmonary Haemorrhage (PH)

Table 4 depicts a comparison of clinical characteristics and morbidity and mortality among patients who had pulmonary haemorrhage compared with those who did not.

266 This shows that females had a significantly higher risk of developing PH than males. The PH group 267 required significantly higher non-invasive ventilation, intubation and ICU care and had a higher number of days in ICU and in hospitalization. Out of the patients who had PH, all most all had two 268 269 or more major complications and had a significantly higher mortality rate compared to the group who had no PH (35.3% vs 5.6%). Nearly 80% patients with PH required management in an ICU. 270 271 Among the haematological parameters, PH group (71,400/µl +46,600) had significantly lower mean platelets counts on admission (104,000µl +69,300) (p=0.03). However, white blood cell 272 273 count on admission was not significantly between the two groups.

Table 4: Characteristics of complications and morbidity among patients having pulmonary haemorrhage (PH) in severe Leptospirosis

No PH	РН	p-value

Number o	f patients	54	34	-
		(61.4%)	(38.6%)	
Age		45.2 <u>+</u> 17.8	45.7 <u>+</u> 13.4	0.96
Gender	Male	51	27	<0.05*
		(57.9%)	(30.7%)	
	Female	3 (3.4%)	7 (7.8%)	
Highest	serum	410.0 <u>+</u> 210	397.9 <u>+</u> 199	0.79
creatinine		.6	.3	
Oxygen su	upport	15	33	<0.01*
		(31.3%)	(68.8%)	
Patients	with	9 (16.7%)	27	<0.01*
significant	t acute		(79.4%)	
haemoglo	bin			
reduction				
Highest	acute	1.14 <u>+</u> 1.1	2.8 <u>+</u> 1.4	<0.01*
haemoglo	bin			
reduction	prior to			
transfusion	n			
Number of	f patients in	5 (9.3%)	27	<0.01*
ICU			(79.4%)	
Days in IC	CU	4 <u>+</u> 1.8	7.96 <u>+</u> 5.4	0.01*
Number	of patients	8 (14.8%)	32	<0.01**
with 3 or	more major		(94.1%)	
complicati	ions			
Total hos	pitalization	5.57 <u>+</u> 2.1	11.3+8.2	<0.01**
days				

Mortality	3/54	12/34	<0.01*
	(5.6%)	(35.3%)	

276

277

278 Non-invasive and invasive treatment modalities used in patients with severe Leptospirosis

Next, we analysed the treatment modalities used in patients with severe Leptospirosis. All patients received antibiotics. Penicillin, ceftriaxone and doxycycline were the most frequently used antibiotics either alone or in combination: Penicillin or Ceftriaxone monotherapy for 27.3%, penicillin and doxycycline for 13.6%, ceftriaxone and doxycycline for 38.6%. Methylprednisolone was administered to 56(63.6%) and intravenous immunoglobulin (IV Ig) was given to 22(25.0%) patients. Tranexamic acid was given to 49(55.7%) patients.

Sixteen (18.2%) patients required dialysis. Two patients required continuous renal replacement therapy (CRRT) concurrently during ECMO. Supplementary oxygen to 55.7%, NIV (CPAP) to 21.6% and intubation and ventilation to 36.4%, were required. Plasmapheresis was performed in 39(44.3%) and 6 (6.6%) required ECMO.

ECMO in patients with Leptospirosis

290 ECMO was required in 6 (6.6%) patients with severe pulmonary haemorrhage. Eligibility of 291 ECMO was decided on the severity of respiratory failure calculated by the 'Murray score' which consist of PaO2/FiO2 (P/F) ratio, extent of alveolar involvement on chest radiograph and peak 292 end-expiratory pressure (PEEP) in the ventilator setting[24], physician's discretion and the 293 294 presence of other co-morbidities. All patients had evidence of severe respiratory failure with 295 Murray scores of 3.25 or above and poor oxygenation despite high ventilator settings. They had a 296 mean P/F (paO2/FiO2) ratio of 93 before ECMO. All had dense bilateral diffused opacities in the 297 chest radiograph (Supplementary: Figure 1a,b). All underwent veno-venous ECMO and were supported by ECMO for a mean duration of 151.4 hours (+ 55.83). They were intubated and 298 299 ventilated for a mean of 12 days (+5.70) and were in ICU for a mean 14.8 +5.44 days (total of 118 300 days). All required renal replacement therapy (RRT). Serial chest radiographs of these patients 301 typically showed resolution of alveolar shadows within 4 to 5 days after initiation of ECMO

302 (Supplementary: Figure 1c,d,e). Four got completely cured and were well at 1- and 3-month 303 follow-up. Two patients succumbed despite ECMO therapy (Supplementary: Table 1).

304 **Overall morbidity and mortality in patients with Leptospirosis**

305 Overall, the mean duration of hospitalization was $8.07(SD\pm5.9)$ days. Thirty-two (36.4%) 306 intubated and ventilated and received ICU care for a mean of 6.73 (±4.9) days. Out of them, 17 307 received ICU care for <7days, 4 for 7-14days and 6 for more than 2 weeks. The patients were 308 intubated and ventilated for mean days of 5.97 (SD±4.8) days.

The case fatality rate of the study sample was 17% with 15 deaths. Patients who developed PH and FHF had a mortality rate of 35.2% and 54.5%, respectively.

The fatality rate of patient with pulmonary haemorrhage who has undergone plasmapheresis is 312 32.3%. Direct comparison for efficacy was not made as the majority (91.2%) of patients with

pulmonary haemorrhage have undergone plasmapheresis and only 3 in PH group did not receive

314 plasmapheresis.

315 Spatial distribution of the abundance of Leptospirosis cases

Total leptospirosis cases, Leptospirosis cases with pulmonary haemorrhage and the number of deaths due to Leptospirosis were mapped for Galle district of Sri Lanka. Figure 1 illustrates that Elpitiya and Yakkalamulla DS divisions are the hot spots for overall leptospirosis cases and Leptospirosis cases with pulmonary haemorrhage (Figure 1 (a) and (b)). On the contrary, Neluwa DS division had the highest death rate due to leptospirosis among all divisions (Figure 1 (c)).



321



324 **Discussion**

In this prospective study, we observed that pulmonary hemorrhage (PH) and hemodynamic instability early in the presentation were significantly associated with mortality. In Galle, PH were present in one-third and FHF was present in 12.5% of patients with severe leptospirosis. We observed that 80% of patients requiring ICU admission had pulmonary hemorrhage, warning us of the significant morbidity in this group. Hepatic involvement with FHF is considered as an unusual clinical manifestation of severe leptospirosis[25, 26], and has only been reported in several instances[21]. Features of fulminant hepatitis were not present early in the illness and developed

332 in patient who require inotropic support which indicate that the pathogenesis could be related to 333 ischaemic liver injury than direct hepatic involvement. However, the presence indicated risk of 334 morbidity and mortality. Therefore, other than the routinely performed hematological tests and renal function tests, we suggest that focused examination and investigations should be performed 335 for early detection of PH and FHF. We suggest to perform prothrombin time (INR), transaminases, 336 hemoglobin reduction, chest radiograph, monitor for hypoxia to identify these complications early. 337 AKI presented as the only manifestation in the majority and other organ complications usually 338 associate with AKI. The presence of a single organ related complication is associated with lesser 339 mortality and with each addition of each organ related complication an increase in mortality is 340 observed. Additionally, we have identified hot spots area of leptospirosis cases and deaths are 341 prevalent in Galle district. This would give us more understanding on how to triage these patients 342 343 that require strict monitoring and supportive care.

344 Septic shock due to leptospirosis is an under-recognised complication. We also noticed that 345 hemodynamic instability is observed in two-thirds of patients with severe leptospirosis. Most of them required inotropic support, where 50% required 2 or more inotropes. It was observed that the 346 347 septic shock in Leptospirosis is much difficult to manage than septic shock due to other conventional bacterial organism. However, comparative studies on clinical and cytokine correlated 348 349 will be of value to understand the pathogenesis. It has been suggested that delay in treating patients with antibiotics and intravenous hydration was an important factor in mortality[28]. Fluid 350 351 management in severe leptospirosis is more challenging than bacterial sepsis due to the co-352 occurrence of AKI, myocarditis or multiple organ dysfunction syndrome. Additionally, we should 353 be aware that myocardial dysfunction and severe bleeding can mimic septic shock. Therefore, it 354 has been suggested that a more conservative fluid management approach may be more appropriate in complicated leptospirosis than managing according to standard sepsis guidelines, given the high 355 mortality associated with pulmonary involvement etc[29]. Yilmaz et al. examined ICU patients 356 357 and found that the clinical and laboratory findings of leptospirosis are similar to those of sepsis. They recommended to think about leptospirosis while examining a patient with SIRS/sepsis 358 etiology in an area endemic for leptospirosis[30]. In a study done in a tropical Australian setting, 359 they have suggested that prompt ICU support, early antibiotics, conservative fluid resuscitation, 360 protective ventilation strategies, traditional thresholds for RRT initiation, and corticosteroid 361 362 therapy, associated with a very low case-fatality rate[31]. Given the high incidence of hemodynamic instability in our group, we should be more vigilant that septic shock, bleeding and
 myocarditis should be identified promptly and managed accordingly.

Although, we could not find any symptoms present on admission or hematological parameters other than SGOT, that can predict mortality; atrial fibrillation, significant acute hemoglobin reduction, longer duration of shock, requirement of intubation and ICU care were important clinical indicators predicting mortality. It has been reported that disproportionate exaggerated rise of SGOT associated with grave prognosis in the late phase of leptospirosis in a limited number of patients[32]. However, we observed that SGOT can predict mortality at an early phase up to 5 days after the onset of fever.

372 There is a dearth of evidence regarding the extent of hemoglobin reduction detectable in patients 373 with leptospirosis associated pulmonary hemorrhage. We observed that in the PH group, the 374 majority had a significant hemoglobin reduction on 4-6 days after symptom onset. We also observed a mean maximum hemoglobin reduction of 5.6g/dl in patients with PH. This hemoglobin 375 376 reduction was observed despite efforts to immediately resuscitate and transfuse patients having 377 acute bleeding. Due to the fact that acute hemoglobin reduction predicted mortality, we suggest that it is advisable to cross match 4-5 units of blood upon suspicion of PH. Moreover, in a 378 379 leptospirosis endemic area of Brazil, they have noted that 13% had gastrointestinal bleeding while 380 a similar percentage developed pulmonary hemorrhages [27]. Therefore, it is plausible that other than pulmonary hemorrhages, leptospirosis could lead to concealed bleeding elsewhere, judging 381 382 from the fact that significant hemoglobin reduction was observed in nearly 15% of patients who did not have features to suggest pulmonary hemorrhages in our study. 383

384 As we have only included patients with one or more complication related to leptospirosis, we 385 consider that these patients represent a potentially severe group that needs hospital care and advanced treatment modalities. Moreover, our study includes a large prospective case series of 386 387 leptospirosis who underwent ECMO in the world. Altogether, there were 11 reported individual 388 cases and two retrospective studies mentioning 13 patients with ARDS due to leptospirosis[22, 32-389 34] who underwent ECMO. Patients in our study were selected for ECMO when the Murray score 390 was 3-4. ECMO improved oxygenation in these patients who had inadequate oxygenation despite 391 being on maximum ventilatory support. We described 6 patients who underwent ECMO and four 392 survived. Respiratory failure occurring due to pulmonary hemorrhages are transient and reversible,

393 whereas the chances of survival may be improved if they are supported adequately during this 394 critical period. Initiation of ECMO enabled to maintain adequate oxygenation because the lungs 395 could be maintained on 'rest settings' at low ventilatory pressures until haemorrhagic lungs recover. Therefore, 'rest settings' potentially could reduce inotrope requirement due to restoration 396 397 of venous return and tissue perfusion due to lesser ventilatory pressures. Due to prevalent septic shock clinical phenotype requiring multiple inotropes, theoretically ECMO would assist to 398 399 stabilise haemodynamic parameters initially. Traditionally, severe bleeding has been a relative 400 contraindication to extra-corporeal membrane oxygenation (ECMO), which requires systemic anticoagulation to maintain circuit patency. However, cases of diffuse alveolar haemorrhage have 401 been reported to be successfully managed using ECMO[35]. In our case series, standards levels of 402 ACT were used and any aggravation of bleeding was not observed. This should be used cautiously 403 in patients with PH and anticoagulation should be withheld immediately with exacerbation of 404 405 bleeding. In a tropical setting where funding and resources are sparse, we consider this a major 406 step forward to improve mortality in patients with severe pulmonary haemorrhage due to 407 Leptospirosis.

Ideally, further observational studies would have been beneficial to decide on surrogate respiratory parameters (Murray score, P/F ratio, oxygenation index) where ECMO can be initiated. This would invite the need for further research or trials to observe a benefit of ECMO and plasma exchange in patients with pulmonary haemorrhage due to Leptospirosis.

412 Conclusions

Pulmonary haemorrhage and haemodynamic instability can be used as early predictors of mortality in severe leptospirosis. Other than the above atrial fibrillation, acute haemoglobin reduction, prolonged shock, elevated SGOT level at admission can be used as warning signs of mortality. These findings will have a significant effect on the management of patients in taking decisions on triaging and escalation of care. Identifying disease hot spots of leptospirosis cases and deaths will help in decisions to improve regional hospital facilities and organised transfer for advanced care.

419 Ethical approval

420 Ethical approval for the study was obtained from the Ethical Review Committee, Faculty of

421 Medicine, University of Ruhuna. Approval for conducting the research at THK was obtained from

422 the Director of the THK. Informed consent was taken from all study participants.

423 Author contributions

424 CLF, NJD, CKB are joint senior authors involved in conceptualisation, conducting and editing of 425 the manuscript. SK analysed the GPS data and created figures. Other authors contributed in patient 426 recruitment, data collection, data analysis and writing initial draft. All authors contributed 427 significantly to this work.

428 Funding

429 None.

430 Acknowledgement

431 We would like to thank the ECMO team: Dr T Harischandra, Dr K Withanaarachchi and Dr RK

432 Firmin who did an incredible service to facilitate ECMO support and Dr T Weliwita who

433 performed plasma exchange. We are grateful to Dr Lilani Karunanayake and the Medical Research

434 Institute for performing confirmatory investigations to diagnose leptospirosis and also sharing the

435 investigation data with us.

436 **References**

- 437 1. Picardeau M. Leptospirosis: Updating the Global Picture of an Emerging Neglected Disease.
- 438 PLoS Negl Trop Dis. 2015;9(9):e0004039. doi: 10.1371/journal.pntd.0004039. PubMed PMID:
- 439 26402855; PubMed Central PMCID: PMCPMC4581693.
- Lau CL, Smythe LD, Craig SB, Weinstein P. Climate change, flooding, urbanisation and
 leptospirosis: fuelling the fire? Trans R Soc Trop Med Hyg. 2010;104(10):631-8. Epub 2010/09/04. doi:
 10.1016/j.trstmh.2010.07.002. PubMed PMID: 20813388.
- 443 3. Agampodi S, Peacock SJ, Thevanesam V. The potential emergence of leptospirosis in Sri Lanka.
- 444 The Lancet Infectious diseases. 2009;9(9):524-6. Epub 2009/08/22. doi: 10.1016/s1473-3099(09)70211 445 7. PubMed PMID: 19695489.
- 446 4. Levett PN. Leptospirosis. Clinical microbiology reviews. 2001;14(2):296-326. doi:
- 447 10.1128/cmr.14.2.296-326.2001.
- 448 5. Zaki SR, Shieh WJ. Leptospirosis associated with outbreak of acute febrile illness and pulmonary 449 haemorrhage, Nicaragua, 1995. The Epidemic Working Group at Ministry of Health in Nicaragua. Lancet
- 450 (London, England). 1996;347(9000):535-6. Epub 1996/02/24. PubMed PMID: 8596276.
- 451 6. Segura ER, Ganoza CA, Campos K, Ricaldi JN, Torres S, Silva H, et al. Clinical spectrum of
- 452 pulmonary involvement in leptospirosis in a region of endemicity, with quantification of leptospiral
- 453 burden. Clin Infect Dis. 2005;40(3):343-51. Epub 2005/01/26. doi: 10.1086/427110. PubMed PMID:
- 454 15668855; PubMed Central PMCID: PMCPMC2366057.

455 7. Papa A, Theoharidou D, Antoniadis A. Pulmonary involvement and leptospirosis, Greece. Emerg 456 Infect Dis. 2009;15(5):834-5. Epub 2009/05/01. doi: 10.3201/eid1505.080270. PubMed PMID: 457 19402988; PubMed Central PMCID: PMCPMC2687020. 458 Gouveia EL, Metcalfe J, de Carvalho AL, Aires TS, Villasboas-Bisneto JC, Queirroz A, et al. 8. 459 Leptospirosis-associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil. Emerg Infect Dis. 460 2008;14(3):505-8. Epub 2008/03/08. doi: 10.3201/eid1403.071064. PubMed PMID: 18325275; PubMed 461 Central PMCID: PMCPMC2570821. 462 9. McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Current opinion in infectious 463 diseases. 2005;18(5):376-86. Epub 2005/09/09. PubMed PMID: 16148523. 464 10. Devadas S, Das J, Liu C, Zhang L, Roberts AI, Pan Z, et al. Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity. 2006;25(2):237-47. Epub 2006/08/12. doi: 465 466 10.1016/j.immuni.2006.06.011. PubMed PMID: 16901729. 467 Panaphut T, Domrongkitchaiporn S, Thinkamrop B. Prognostic factors of death in leptospirosis: a 11. prospective cohort study in Khon Kaen, Thailand. Int J Infect Dis. 2002;6(1):52-9. Epub 2002/06/05. 468 469 PubMed PMID: 12044303. 470 Marotto PC, Nascimento CM, Eluf-Neto J, Marotto MS, Andrade L, Sztajnbok J, et al. Acute 12. 471 lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated with 472 mortality. Clin Infect Dis. 1999;29(6):1561-3. Epub 1999/12/10. doi: 10.1086/313501. PubMed PMID: 473 10585813. 474 13. Warnasekara J, Koralegedara I, Agampodi S. Estimating the burden of leptospirosis in Sri Lanka; 475 a systematic review. BMC Infect Dis. 2019;19(1):119. Epub 2019/02/08. doi: 10.1186/s12879-018-3655-476 y. PubMed PMID: 30727968; PubMed Central PMCID: PMCPMC6364467. 477 Herath N, Uluwattage W, Weliwitiya T, Karunanayake L, Lekamwasam S, Ratnatunga N, et al. 14. 478 Sequel and therapeutic modalities of leptospirosis associated severe pulmonary haemorrhagic syndrome 479 (SPHS); a Sri Lankan experience. BMC Infect Dis. 2019;19(1):451. Epub 2019/05/23. doi: 480 10.1186/s12879-019-4094-0. PubMed PMID: 31113404; PubMed Central PMCID: PMCPMC6530063. 481 Ko AI, Galvão Reis M, Ribeiro Dourado CM, Johnson WD, Jr., Riley LW. Urban epidemic of 15. 482 severe leptospirosis in Brazil. Salvador Leptospirosis Study Group. Lancet (London, England). 483 1999;354(9181):820-5. Epub 1999/09/15. doi: 10.1016/s0140-6736(99)80012-9. PubMed PMID: 484 10485724. 485 Haake DA, Levett PN. Leptospirosis in humans. Current topics in microbiology and immunology. 16. 486 2015;387:65-97. doi: 10.1007/978-3-662-45059-8 5. PubMed PMID: 25388133. 487 17. Pappachan MJ, Mathew S, Aravindan KP, Khader A, Bharghavan PV, Kareem MM, et al. Risk 488 factors for mortality in patients with leptospirosis during an epidemic in northern Kerala. Natl Med J 489 India. 2004;17(5):240-2. Epub 2005/01/11. PubMed PMID: 15638302. 490 18. Al Hariri YK, Sulaiman SAS, Khan AH, Adnan AS, Al Ebrahem SQ. Mortality of leptospirosis 491 associated acute kidney injury (LAKI) & predictors for its development in adults: A systematic review. Journal of Infection and Public Health. 2019;12(6):751-9. doi: https://doi.org/10.1016/j.jiph.2019.06.014. 492 493 Agampodi SB, Dahanayaka NJ, Bandaranayaka AK, Perera M, Priyankara S, Weerawansa P, et 19. 494 al. Regional differences of leptospirosis in Sri Lanka: observations from a flood-associated outbreak in 495 2011. PLoS Negl Trop Dis. 2014;8(1):e2626. doi: 10.1371/journal.pntd.0002626. PubMed PMID: 496 24454971; PubMed Central PMCID: PMCPMC3894175. Dassanayake DL, Wimalaratna H, Nandadewa D, Nugaliyadda A, Ratnatunga CN, Agampodi 497 20. 498 SB. Predictors of the development of myocarditis or acute renal failure in patients with leptospirosis: an 499 observational study. BMC Infect Dis. 2012;12:4. Epub 2012/01/17. doi: 10.1186/1471-2334-12-4. 500 PubMed PMID: 22243770; PubMed Central PMCID: PMCPMC3292442. 501 21. Shintaku M, Itoh H, Tsutsumi Y. Weil's disease (leptospirosis) manifesting as fulminant hepatic 502 failure: Report of an autopsy case. Pathology - Research and Practice. 2014:210(12):1134-7. doi: 503 https://doi.org/10.1016/j.prp.2014.05.002.

- 504 22. Fonseka CL, Lekamwasam S. Role of Plasmapheresis and Extracorporeal Membrane
- 505 Oxygenation in the Treatment of Leptospirosis Complicated with Pulmonary Hemorrhages. Journal of 506 Tropical Medicine. 2018;2018:8. doi: 10.1155/2018/4520185.
- 507 Organization WH. Report of the first meeting of the leptospirosis burden epidemiology reference 23. 508 group. 2010.
- 509 24. Organization ELS. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support
- 510 (Version 1.4).
- 511 25. Spichler AS, Vilaça PJ, Athanazio DA, Albuquerque JOM, Buzzar M, Castro B, et al. Predictors
- 512 of lethality in severe leptospirosis in urban Brazil. The American journal of tropical medicine and 513 hygiene. 2008;79(6):911-4. PubMed PMID: 19052303.
- 514 26. Wang HK, Lee MH, Chen YC, Hsueh PR, Chang SC. Factors associated with severity and
- 515 mortality in patients with confirmed leptospirosis at a regional hospital in northern Taiwan. J Microbiol 516
- Immunol Infect. 2018. Epub 2018/06/24. doi: 10.1016/j.jmii.2018.05.005. PubMed PMID: 29934034. 517 Daher EF, Lima RS, Silva Júnior GB, Silva EC, Karbage NN, Kataoka RS, et al. Clinical 27.
- 518 presentation of leptospirosis: a retrospective study of 201 patients in a metropolitan city of Brazil. Braz J 519 Infect Dis. 2010;14(1):3-10. Epub 2010/04/30. PubMed PMID: 20428646.
- 520
- Duarte-Neto AN, Croda J, Pagliari C, Soriano FG, Nicodemo AC, Duarte MIS. Severe 28. 521
- Leptospirosis Features in the Spleen Indicate Cellular Immunosuppression Similar to That Found in 522 Septic Shock. Frontiers in immunology. 2019;10:920-. doi: 10.3389/fimmu.2019.00920. PubMed PMID:
- 523 31114579.
- Niwattavakul K, Homvijitkul J, Niwattavakul S, Khow O, Sitprija V. Hypotension, renal failure, 524 29. 525 and pulmonary complications in leptospirosis. Ren Fail. 2002;24(3):297-305. Epub 2002/08/09. doi:
- 526 10.1081/jdi-120005363. PubMed PMID: 12166696.
- 527 Yilmaz H, Turhan V, Yasar KK, Hatipoglu M, Sunbul M, Leblebicioglu H. Characteristics of 30.
- 528 leptospirosis with systemic inflammatory response syndrome: a multicenter study. Annals of clinical
- 529 microbiology and antimicrobials. 2015;14:54-. doi: 10.1186/s12941-015-0117-x. PubMed PMID: 530 26690093.
- 531 31. Smith S, Liu Y-H, Carter A, Kennedy BJ, Dermedgoglou A, Poulgrain SS, et al. Severe
- 532 leptospirosis in tropical Australia: Optimising intensive care unit management to reduce mortality. PLoS 533 neglected tropical diseases. 2019;13(12):e0007929-e. doi: 10.1371/journal.pntd.0007929. PubMed PMID: 534 31790405.
- 535 Delmas B, Jabot J, Chanareille P, Ferdynus C, Allyn J, Allou N, et al. Leptospirosis in ICU: A 32.
- 536 Retrospective Study of 134 Consecutive Admissions. Crit Care Med. 2018;46(1):93-9. doi:
- 537 10.1097/CCM.00000000002825. PubMed PMID: 29116996.
- 538 Barnacle J, Gurney S, Ledot S, Singh S. Leptospirosis as an important differential of pulmonary 33.
- 539 haemorrhage on the intensive care unit: a case managed with VV-ECMO. J Intensive Care. 2020;8:31.
- Epub 2020/05/01. doi: 10.1186/s40560-020-00447-2. PubMed PMID: 32351698; PubMed Central 540 541 PMCID: PMCPMC7183660.
- 542 34. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and 543 economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation
- 544 for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet (London,
- 545 England). 2009;374(9698):1351-63. Epub 2009/09/19. doi: 10.1016/s0140-6736(09)61069-2. PubMed
- 546 PMID: 19762075.
- 547 35. Abrams D, Agerstrand CL, Biscotti M, Burkart KM, Bacchetta M, Brodie D. Extracorporeal
- 548 membrane oxygenation in the management of diffuse alveolar hemorrhage. Asaio j. 2015;61(2):216-8.
- 549 Epub 2014/12/09. doi: 10.1097/mat.000000000000183. PubMed PMID: 25485559.
- 550